Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
REDWOOD CITY, Calif., Oct. 21, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective October 20, 2016, the compensation committee of the company’s board of directors granted 5 new employees options to purchase an aggregate of 62,000 shares of the company’s common stock with a per share exercise price of $30.39, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
